Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Current Valuation Ratios
Historical Valuation Ratios (Summary)
Price to Earnings (P/E)
Price to Operating Profit (P/OP)
Price to Sales (P/S)
Price to Book Value (P/BV)

Gilead Sciences Inc., current price multiples

	Gilead Sciences Inc.	Abbott Laboratories	AbbVie Inc.	Allergan PLC	Amgen Inc.	Biogen Inc.	Bristol-Myers Squibb Co.	Celgene Corp.	Eli Lilly & Co.	Johnson & Johnson	Merck & Co. Inc.	Pfizer Inc.	Regeneron Pharmaceuticals Inc.	Pharmaceuticals & Biotechnology	Health Care
Selected Financial Data
Current share price (P)	$
No. shares of common stock outstanding
Growth rate (g)

Earnings per share (EPS)	$
Next year expected EPS	$
Operating profit per share	$
Sales per share	$
Book value per share (BVPS)	$
Ratios (Price Multiples)
Price to earnings (P/E)
Price to next year expected earnings
Price-earnings-growth (PEG)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-K (filing date: 2019-02-26).

If company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.

Otherwise, if company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.

Gilead Sciences Inc., historical price multiples

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	Price to earnings (P/E)
	Price to operating profit (P/OP)
	Price to sales (P/S)
	Price to book value (P/BV)

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

Ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Gilead Sciences Inc.’s P/E ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.	Gilead Sciences Inc.’s P/OP ratio increased from 2016 to 2017 and from 2017 to 2018.
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Gilead Sciences Inc.’s P/S ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return.	Gilead Sciences Inc.’s P/BV ratio increased from 2016 to 2017 but then declined significantly from 2017 to 2018.

Gilead Sciences Inc., historical P/E calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Net income attributable to Gilead (in millions)
	Earnings per share (EPS)³
	Share price^1, 2
	Ratio
	P/E ratio⁴
	Benchmarks
	P/E Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Allergan PLC
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/E Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/E Ratio, Industry
	Health Care

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

2018 Calculations

³ EPS = Net income attributable to Gilead ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/E ratio = Share price ÷ EPS
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Gilead Sciences Inc.’s P/E ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.

Gilead Sciences Inc., historical P/OP calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Income from operations (in millions)
	Operating profit per share³
	Share price^1, 2
	Ratio
	P/OP ratio⁴
	Benchmarks
	P/OP Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Allergan PLC
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/OP Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/OP Ratio, Industry
	Health Care

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

2018 Calculations

³ Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/OP ratio = Share price ÷ Operating profit per share
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.	Gilead Sciences Inc.’s P/OP ratio increased from 2016 to 2017 and from 2017 to 2018.

Gilead Sciences Inc., historical P/S calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Product sales (in millions)
	Sales per share³
	Share price^1, 2
	Ratio
	P/S ratio⁴
	Benchmarks
	P/S Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Allergan PLC
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/S Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/S Ratio, Industry
	Health Care

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

2018 Calculations

³ Sales per share = Product sales ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/S ratio = Share price ÷ Sales per share
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Gilead Sciences Inc.’s P/S ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.

Gilead Sciences Inc., historical P/BV calculation, comparison to benchmarks

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	No. shares of common stock outstanding¹
	Selected Financial Data (USD $)
	Total Gilead stockholders’ equity (in millions)
	Book value per share (BVPS)³
	Share price^1, 2
	Ratio
	P/BV ratio⁴
	Benchmarks
	P/BV Ratio, Competitors
	Abbott Laboratories
	AbbVie Inc.
	Allergan PLC
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Celgene Corp.
	Eli Lilly & Co.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	P/BV Ratio, Sector
	Pharmaceuticals & Biotechnology
	P/BV Ratio, Industry
	Health Care

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

¹ Data adjusted for splits and stock dividends.

² Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

2018 Calculations

³ BVPS = Total Gilead stockholders’ equity ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

⁴ P/BV ratio = Share price ÷ BVPS
= hidden ÷ hidden = hidden

Ratio	Description	The company
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return.	Gilead Sciences Inc.’s P/BV ratio increased from 2016 to 2017 but then declined significantly from 2017 to 2018.

	Gilead Sciences Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Gilead Sciences Inc. (GILD)

Common Stock Valuation Ratios (Price Multiples)

Current Valuation Ratios

Historical Valuation Ratios (Summary)

Price to Earnings (P/E)

Price to Operating Profit (P/OP)

Price to Sales (P/S)

Price to Book Value (P/BV)